Vimarsana
Biggest News Aggregation in the World

Page 5 - Grant Pickering News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Grant Pickering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Grant Pickering Today - Breaking & Trending Today

Leading Independent Proxy Advisory Firm ISS Recommends that - Vimarsana News

Leading Independent Proxy Advisory Firm ISS Recommends that

Athira Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering –...

Athira Mails Letter to Shareholders Highlighting the - Vimarsana News

Athira Mails Letter to Shareholders Highlighting the

Urges shareholders to vote “FOR” Athira’s highly qualified, independent director nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the...

Ric Kayne Files Definitive Proxy Materials for Athira's 2022 Annual Meeting - Vimarsana News

Ric Kayne Files Definitive Proxy Materials for Athira's 2022 Annual Meeting

Sends Letter to Athira’s Shareholders Seeking Replacement of CEO Dr. Mark LittonHighlights New Management and Shareholder Centric Directors Are Required to Provide Proper Oversight of ATH-1017 Clinical Trials to Maximize Likelihood of SuccessUrges ATHA Shareholders to VOTE the BLUE Proxy Card NEW YORK--(BUSINESS WIR...

Leen Kawas Business Partner Stirs Up More Drama at Athira - Vimarsana News

Leen Kawas Business Partner Stirs Up More Drama at Athira

Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne's calls for a management change.

Athira Pharma : Reports Full Year 2021 Financial Results and Provides Clinical Update - Form 8-K - Vimarsana News

Athira Pharma : Reports Full Year 2021 Financial Results and Provides Clinical Update - Form 8-K

Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update On track to report topline data from ACT-AD Phase 2 Alzheimer's disease study in 2Q22 ... | March 24, 2022